Recent breakthroughs in obesity, Alzheimer’s, and other major disease areas are reshaping pharma R&D priorities and forcing companies to rethink pipeline strategy, payer value communication, and long-term growth. The discussion highlights the importance of learning from both drug development successes and failures, while emphasizing emerging opportunities in areas like cell, gene, and RNA therapies, as well as longevity and healthy aging research, as potential drivers of future industry differentiation.